Diabetes Clinical Trials in Georgia

Showing 101-120 of 528 trials

Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus

NCT04838392

The purpose of this study is to evaluate the effectiveness and safety of the RIGHTEST Continuous Monitoring (CGM) System in adult population with diabetes mellitus.

Diabetes MellitusType 1 DiabetesType 2 Diabetes

Bionime Corporation150 participantsStarted Dec 2024

Guntersville, Alabama, United States • Tucson, Arizona, United States • Canoga Park, California, United States +10 more locations

COMPLETEDPhase 363 miles

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

NCT03371082

Primary Objective: •To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: • To evaluate the percentage of subjects with negative anti-insulin antibodies (AIAs) at baseline who develop confirmed positive AIA up to Week 26, the percentage of baseline in AIA titers between treatment groups, the percentage of subjects with confirmed positive AIA who develop any anti-insulin neutralizing antibodies up to visit Week 26, and percentage of subjects who develop confirmed positive AIA up to visit Week 26 of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®. Safety: •To evaluate the safety of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®. Efficacy: •To evaluate the efficacy of Gan \& Lee Insulin Glargine Injection in comparison with that of Lantus®.

Diabetes Mellitus, Type 1

Gan and Lee Pharmaceuticals, USA576 participantsStarted Oct 2017

Birmingham, Alabama, United States • Fresno, California, United States • Newport Beach, California, United States +82 more locations

PreviousPage 6 of 27Next

Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Diabetes Trials in Other Cities

Dapagliflozin at Discharge on Hospital Heart Failure Readmission

Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Dexcom Continuous Glucose Monitoring in Long-term Care

Pivotal Trial of a Digital Therapeutic for the Treatment of Type 2 Diabetes

Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes

Impact of Acetaminophen on Performance of Guardian™ Sensor (3) in Adults

VasQ External Support for Arteriovenous Fistula

A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.

An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants

Novel Biomarker for Development of T2D

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes

C-myc Biomarker Study for Diabetic Foot Ulcers

The Effect of In-utero Exposure to Metformin in 5-11 Year Old Offspring of Mothers in the MiTy Trial

Control-IQ Technology in Individuals With Type 2 Diabetes

Other Conditions in Georgia